Beximco Pharmaceuticals PLC. announcements
297 Dhaka Stock Exchange announcements for Beximco Pharmaceuticals PLC. (BXPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2018 (15).
- Resumption after record date
Trading of the shares of the Company will resume on 27.11.2018 after record date.
- Suspension for Record date
Trading of the shares of the Company will remain suspended on record date i.e., 26.11.2018 for EGM and AGM.
- Spot News
Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 22.11.2018 to 25.11.2018. Trading of the shares of the Company will remain suspended on record date i.e., 26.11.2018 for EGM and AGM.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 1.86 for July-September, 2018 as against Tk. 1.59 for July-September, 2017; Consolidated NOCFPS was Tk. 1.05 for July-September, 2018 as against Tk. 1.56 for July-September, 2017. Consolidated NAV per share was Tk. 68.59 as on September 30, 2018 and Tk. 63.36 as on September 30, 2017. As the company acquired Nuvista Pharma on 2.4.18, the comparative prior period figures are reported in the consolidated figures.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2018 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2018.
- Dividend Declaration and holding an EGM to amend certain clauses
The Board of Directors has recommended 12.50% cash dividend for the year ended on June 30, 2018. The Board has also decided to hold an EGM to pass Special Resolutions to amend certain Clauses of Memorandum of Association and Articles of Association of the Company. Date of EGM & AGM: 22.12.2018, Time for EGM & AGM: 10:00 AM & 10:30 AM respectively, Venue: Beximco Industrial Park, Sarabo, Kashimpur, Gazipur. Record Date: 26.11.2018. (cont.) (Continuation news of BXPHARMA): The Company has also reported Consolidated EPS of Tk. 6.25, Consolidated NAV per share of Tk. 66.78 and Consolidated NOCFPS of Tk. 4.49 for the year ended on June 30, 2018. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (28.10.2018) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 25, 2018 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2018.
- Credit Rating Result
Credit Rating Information and Services Limited (CRISL) has rated the Company as "AA+" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2017, unaudited financials up to March 31, 2018 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 1.49 for January-March 2018 as against Tk. 1.29 for January-March 2017; EPS was Tk. 4.74 for July 2017-March 2018 as against Tk. 4.03 for July 2016-March 2017. NOCFPS was Tk. 3.83 for July 2017-March 2018 as against Tk. 4.37 for July 2016-March 2017. NAV per share was Tk. 65.26 as on March 31, 2018 and Tk. 60.36 as on March 31, 2017.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 26, 2018 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2018.
- Completes acquisition of a majority stake in Nuvista Pharma Limited
Referring to their earlier news (disseminated by DSE on 08.10.2017) regarding acquiring a majority shareholding (85.22%) in Nuvista Pharma Ltd., the Company has further informed that the Board of Directors of the Company has considered and approved the acquisition of 10,013,474 ordinary shares of Tk. 10.00 each being 85.22% shareholdings of total capital in Nuvista Pharma Limited (formerly Organon Bangladesh Limited), a leading Pharma company in Bangladesh, specializing (cont.) (Continuation news of BXPHARMA): in hormones and steroid drugs, in terms of the decision of the shareholders of the company in its AGM and thus it completed the acquisition. The Government of Bangladesh currently holds 12.92% stake in Nuvista Pharma Limited. (end)
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 1.66 for October-December, 2017 as against Tk. 1.47 for October-December, 2016; EPS was Tk. 3.25 for July-December, 2017 as against Tk. 2.74 for July-December, 2016. NOCFPS was Tk. 3.14 for July-December, 2017 as against Tk. 2.56 for July-December, 2016. NAV per share was Tk. 63.77 as on December 31, 2017 and Tk. 59.07 as on December 31, 2016.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2018 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2017.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2017 to the respective shareholders' Bank Accounts through BEFTN system.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.